Key Players
Competitive Landscape
Two broad supplier groups compete in the Skin Structure Infections Market: diversified pharmaceutical companies and specialist anti-infective developers. The first group brings manufacturing scale and formulary relationships, while specialists compete through focused products with newer labels or more flexible dosing.
Activity since 2025 has centered on lifecycle evidence and market access. Paratek presented pooled NUZYRA safety findings from Phase 3 studies in 2026. Basilea reported USA commercial availability of Zevtera in May 2025, while the SIVEXTRO label expanded to younger pediatric patients in April 2025. Buyers continue to compare pathogen coverage and route flexibility, followed by stewardship fit.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In April 2026, Paratek announced pooled safety findings from four Phase 3 NUZYRA studies, including two ABSSSI trials. | Hospitals need evidence that supports therapy selection across susceptible pathogens and patient settings. | Lifecycle evidence is becoming more important in formulary review after initial approval. | Oral and intravenous continuity can support outpatient treatment after hospital assessment. |
| In May 2025, Basilea reported USA commercial availability of Zevtera through Innoviva Specialty Therapeutics. | Hospitals need additional options for adult ABSSSI involving susceptible organisms, including MRSA. | Commercial access is following recent regulatory approval through specialist hospital platforms. | Hospital and outpatient distribution can expand use where the label and stewardship criteria are met. |
| In April 2025, the FDA expanded SIVEXTRO labeling to pediatric ABSSSI patients at least 26 weeks gestational age and weighing at least 1 kg. | Pediatric care requires age-appropriate labeling and weight-based dosing evidence. | Lifecycle management is widening patient coverage for established anti-infective products. | Pediatric hospital formularies gain a labeled oxazolidinone option across intravenous and eligible oral use. |
Pfizer Inc., AbbVie Inc., GSK plc, Melinta Therapeutics, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd. and Glenmark Pharmaceuticals Ltd. remain relevant through branded products or broader pharmaceutical supply outside the three mapped developments.
Source: Future Market Insights, Skin Structure Infections Market report, 2026-2036.
Pfizer and Melinta show the broadest branded depth in this evidence comparison. Merck supports oral and intravenous continuity through SIVEXTRO, while Paratek and Basilea have the most recent market-specific activity. This comparison reflects product evidence and does not rank company revenue.
Who leads the Skin Structure Infections Market?
Pfizer shows broad branded depth through ZYVOX and TYGACIL, while Melinta also spans several products with skin-infection indications. Merck, Paratek and Basilea compete through differentiated route or lifecycle evidence. No public evidence reviewed for this article supports a definitive revenue-share leader.
Which suppliers have documented approvals?
Zevtera received FDA approval in April 2024 and became commercially available in the United States in May 2025 through Innoviva Specialty Therapeutics. The SIVEXTRO label was revised in April 2025 to include pediatric ABSSSI patients who meet the stated gestational-age and weight thresholds.
Which companies provide community-acquired skin and skin structure infection products?
Pfizer, Merck, AbbVie, Melinta, Paratek and Basilea have current products with skin or skin-structure infection indications in the reviewed official materials. Their portfolios differ by drug class and route, followed by dosing schedule and pediatric coverage.
Which suppliers serve the United States and South Korea?
The reviewed evidence confirms USA labeling or commercialization for several products with skin-infection indications. South Korean access was not documented consistently at product level across the company group, so local registrations and distribution partners should be checked before corporate presence is treated as product availability.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Pfizer Inc. | Branded systemic antibacterials | ZYVOX provides oral and intravenous linezolid, while TYGACIL provides intravenous tigecycline for complicated skin and skin structure infections. |
| Merck & Co., Inc. | Oxazolidinone treatment continuity | SIVEXTRO provides oral and intravenous tedizolid for ABSSSI, with pediatric labeling expanded in April 2025. |
| AbbVie Inc. | Long-acting glycopeptide therapy | DALVANCE provides single-dose or two-dose intravenous treatment for ABSSSI and has a pediatric indication. |
| GSK plc | Diversified pharmaceutical group | No current ABSSSI-specific branded product was confirmed in the reviewed official materials. |
| Melinta Therapeutics, Inc. | Hospital and outpatient anti-infectives | BAXDELA provides oral and intravenous treatment, while KIMYRSA and ORBACTIV offer long-acting intravenous options for ABSSSI. |
| Paratek Pharmaceuticals, Inc. | Oral and intravenous tetracycline-class therapy | NUZYRA provides once-daily oral and intravenous treatment for adult ABSSSI, supported by further Phase 3 safety analysis in 2026. |
| Novartis AG | Diversified pharmaceutical group | No current ABSSSI-specific branded product was confirmed in the reviewed official materials. |
| Teva Pharmaceutical Industries Ltd. | Generic medicines manufacturer | The company adds generic manufacturing reach, although no current ABSSSI-specific branded product was confirmed in the reviewed official materials. |
| Glenmark Pharmaceuticals Ltd. | Generic medicines manufacturer | The company adds generic manufacturing reach, although no current ABSSSI-specific branded product was confirmed in the reviewed official materials. |
| Basilea Pharmaceutica Ltd. | Hospital anti-infective developer and licensor | Zevtera provides intravenous ceftobiprole for adult ABSSSI and became commercially available in the United States through Innoviva in May 2025. |
Research Methodology
The companies shown here illustrate market structure rather than corporate scale or revenue rank. Inclusion requires public evidence of an ABSSSI or skin-structure infection product, a relevant approval, commercial activity or broader supply participation. Company materials and regulatory labels were used to confirm capabilities, while local registrations remain attached to the specific product and entity named in each source. Portfolio scores reflect only the evidence reviewed for this article. They do not extend unrelated anti-infective strengths into the comparison, and they do not treat corporate presence as proof of product availability in every country.
